Overview

Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study will describe postoperative pain management for spine surgery patients receiving liposomal bupivacaine (Exparel®) compared to patients not receiving the drug.
Phase:
Phase 4
Details
Lead Sponsor:
Allina Health System
Collaborator:
Twin Cities Spine Center
Treatments:
Bupivacaine